Voriconazole
- Generic Name
- Voriconazole
- Brand Names
- Vfend, Voriconazole Hikma (previously Voriconazole Hospira), Voriconazole Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H14F3N5O
- CAS Number
- 137234-62-9
- Unique Ingredient Identifier
- JFU09I87TR
- Background
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increased affinity of voriconazole for 14-alpha ...
- Indication
For the treatment of esophageal candidiasis, cadidemia, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp.
- Associated Conditions
- Aspergillosis of the Central Nervous System, Aspergillosis of the Liver, Candidemia, Candidiasis, Coccidioidomycosis, Endocarditis caused by Aspergillus, Esophageal Candidiasis, Fungal Infections, Fungal meningitis caused by Exserohilum Infection, Fusarium infection, Histoplasmosis, Invasive Aspergillosis, Osteomyelitis caused by Aspergillus, Penicillium marneffei infection, Peritonitis caused by Aspergillus, Scedosporium Infection, Sinusitis aspergillus, Aspergillus endophthalmitis, Refractory Oral Candidiasis
- Associated Therapies
- -
CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients
- Conditions
- Interventions
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2014-04-01
- Lead Sponsor
- dingshifang
- Target Recruit Count
- 200
- Registration Number
- NCT02100761
- Locations
- 🇨🇳
Qilu Hospital, Jinan, Shandong, China
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT02014558
- Locations
- 🇺🇸
Site US10018, Hershey, Pennsylvania, United States
🇺🇸Site US10015, Chicago, Illinois, United States
🇺🇸Site US10020, Hackensack, New Jersey, United States
Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2021-03-12
- Target Recruit Count
- 15
- Registration Number
- NCT01950507
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT01787032
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Ingelheim, Germany
A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)
- Conditions
- Interventions
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 585
- Registration Number
- NCT01782131
Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2013-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13
- Registration Number
- NCT01660334
Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis
- Conditions
- Interventions
- First Posted Date
- 2012-06-18
- Last Posted Date
- 2017-12-12
- Target Recruit Count
- 50
- Registration Number
- NCT01621321
- Locations
- 🇮🇳
Postgraduate Institute of Medical Education and Research, Chandigarh, India
Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy
- Conditions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Martin-Luther-Universität Halle-Wittenberg
- Target Recruit Count
- 9
- Registration Number
- NCT01539330
- Locations
- 🇦🇹
Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2012-01-04
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 292
- Registration Number
- NCT01503515
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT01383993
- Locations
- 🇯🇵
Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Aichi, Japan
🇯🇵Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
🇯🇵Sapporo Hokuyu Hosipital, Sapporo, Hokkaido, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.